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E-mail address: mcrh@deb.uminho.pt (M. HenriquMonoclonal antibodies (mAbs) are currently used for many diagnostic and therapeutic applications. The
high demand for these biopharmaceuticals has led to the development of large-scale manufacturing pro-
cesses, with productivity improvements being mainly achieved by optimization of bioreactor systems.
However, more recently, the early steps of production, previous to bioreactor culture, have been pre-
sented as alternative areas where productivity enhancements can be achieved. Thus, this review
describes the progress made for the improvement of productivity in mammalian expression systems
for the high production of mAbs. Advances in the development of mAb-producing cell lines are being
made, particularly regarding expression vector design and methods used for transfection, with the intent
to create a reproducible methodology. Selection of the most suitable clones is also a critical step that can
be improved, by including variables other than the expression level, which is still the common practice.
Furthermore, strategies of cell engineering, although still mostly based on trial-and-error experimenta-
tion and not in standard protocols, hold great interest to improve cell growth and productivity, as well
as product quality in the future. Improvements of the initial steps of the production process would not
only result in cells with higher expression ability, but would also speed-up the process development.
 2009 Elsevier B.V. All rights reserved.1. Introduction
The number of monoclonal antibodies (mAbs) currently used in
clinical trials and already approved for therapeutic applications has
increased signiﬁcantly in recent years [1–3]. They are currently
used in the treatment of cancer, autoimmune disorders, allergic
diseases, transplantation and anti-idiotype vaccine, among others
[4].
The development of improved production of mAbs and other re-
combinant proteins is often associated with progress in cell culture
technology and particularly in mammalian cell culture. The pro-
duction of mAbs in mammalian cells consists of a long process that
involves steps of transfection of the gene of interest into the cells,
selection of clones, adaptation to different culture conditions (usu-
ally suspension and serum-free medium), culture in bioreactors
and scale-up to industrial level. Indeed, due to the high demands
for mAbs, a large-scale process needs to be established, with levels
of production that meet the market needs (several kg/day) [5,6].
For this, the optimization of mAb production is usually performed
in bioreactors, by testing different bioreactor modes of operation
and culture parameters. However, even in the earlier steps of pro-
duction, previous to scale-up, several variants are in play, inﬂuenc-ll rights reserved.
hnology and Bioengineering,
o, 4710-057 Braga, Portugal.
es).ing the ﬁnal results of mAb production. In fact, it is known that
several parameters such as cell line type, cell size and cell cycle
[7], product characteristics, vector/promoter of transfection [8,9],
methods of transfection and clone selection, post-transcription
regulation [10] and growth medium, among many others, have
great impact on the ﬁnal productivity levels obtained. Therefore,
the optimization of mAb production should start in the ﬁrst few
steps of the process, and not only during bioreactor culture.
The present goal is to outline the advances that have been made
in mAb optimization, pre-scale-up processes its major achieve-
ments, and problems and limitations encountered that still need
to be surpassed as well as the areas that hold major interest for fu-
ture research.
2. Expression system
As already mentioned, mammalian cells are currently the main
hosts for commercial production of therapeutic proteins, including
mAbs [11–14]. Indeed, although a variety of either prokaryotic or
eukaryotic (insect [15,16] and plant cells [17,18]) systems have
been used [19], the fact that mammalian cells have the ability to
perform correct (human-like) post-translational modiﬁcations
[20] makes them the most suitable system.
Production of mAbs in these cells necessarily begins with the
development of a suitable cell line, determined by the selection
of cell type. In order to be apt for biopharmaceutical application,
cells must have the following characteristics: (i) support high-level
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ble cell density and genetic stability; (ii) be scalable; (iii) have
appropriate abilities for post-translational processing and (iv) al-
low appropriate characterization for human safety [4]. Apart from
these features, there is no restriction on the type of cell used [4],
and several mammalian cell lines have been reported for achieving
successful results (expression levels on the order of 10–100 pg/
cell/day) [4,14]. Furthermore, the choice of the best suitable cell
line may also depend on the product application.
If the aim is to produce small-scale quantities of mAbs, as for
preliminary investigation (biochemical and biophysical) analysis,
then African green monkey kidney (COS) cells may be appropriate
[19]. Indeed, they have been used for transient expression of active
antibodies since 1987 [21,22]. However, they are not the most suit-
able cells for large-scale processes of production, since they lose
the production ability over time. Actually, if the aim is large-scale
production, the most currently used cells for this application are
Chinese hamster ovary (CHO) cells, which have assumed an
increasing importance both in laboratory [21,23] and biopharma-
ceutical high-level mAb production [13,14,20,24,25]. Their suit-
ability for large-scale and stable production of mAbs is related to
their advantages of safety for use in humans [11,19], resemblance
between glycan structure of their product with the natural human
mAb [11,26], ease of transfection, presence of a powerful gene
ampliﬁcation system, ease of adaptation to growth in suspension
[27] and serum-free medium, and the ability to grow at high den-
sities [11,19].
Other cells commonly used for large-scale production are mye-
loma cells [13,14,28–30], such as SP 2/0, YB 2/0, NS0 and
P3X63.Ag8.653 [28]. Similar to CHO cells, they are able to grow
at high densities, in suspension culture and serum-free medium,
and are readily transfected [19]. Although recently their use has
become less frequent, there are at least four Food and Drug Admin-
istration (FDA)-approved mAb drugs produced by these cells (spe-









Hybridoma cells were also commonly used for mAb production
for several decades [32,33]. However, their sensitivity to environ-
mental changes [34,35] and toxic compounds formed during cell
growth [36,37], as well as to shear and bubble damage in bioreac-
tors [3], which complicate their large-scale culture, have reduced
the application of these cells.
Interest in other cell lines for mAb production has risen, such as
baby hamster kidney (BHK) [38,39], human embryonic kidney
(HEK-293) [39,40] and human retina-derived PER-C6 cells
[41,42]. This last cell line has recently been reported to produce
signiﬁcant levels of recombinant products, including mAbs, in a
stable manner, being easily adapted to different growth conditions,
not requiring gene ampliﬁcation (thus providing rapid clone gener-
ation) nor adding non-human glycan structures to proteins [41,43].
As demonstrated, a variety of cell lines can be used for mAb pro-
duction, although not all have the ability to achieve high-level of
expression. However, the levels of expression appear to be more
dependent on the combination of host cell, expression vector,
transfection and selection strategy, rather than on only the charac-
teristics of the host cell [4,29].3. Transfection
After the selection of the most suitable cell type for the applica-
tion intended, cells are transfected to obtain mAb-producing
clones. Transfection is the introduction of the product DNA into
the cells and involves different steps, from the design of the
expression vector and the deﬁnition of the transfection method(expression system and DNA delivery system) to the selection of
the transfected cells with the most desirable characteristics.
3.1. Expression vector
The expression of heterologous proteins in mammalian cells re-
quires the use of specialized vectors [44,45] to transfer the product
gene into the cells [45]. These vectors should display three main
features: expression levels independent from the site of integration
in the genome, expression levels correlated with the number of
integrated transgene copies and maintenance of expression efﬁ-
ciency over time [46]. Due to these requirements, mammalian vec-
tors are usually plasmids. Plasmids are circular DNAmolecules that
exist in bacterial cells apart from their main chromosome and pos-
sess at least one replication origin [45]. This allows plasmids to
replicate within cells, independently from bacterial or eukaryotic
chromosomes [45]. The ability to express genes in mammalian
cells requires a cassette that consists of two types of elements: pro-
moter/enhancer elements that drive mRNA transcription and se-
quences that help to stabilize or enhance translation of the
primary transcript [4].
Promoters/enhancers: promoters are elements that drive the
expression of the recombinant gene, promoting and accurately
positioning the beginning of transcription, while enhancers are ele-
ments that augment transcription [4,47]. For the expression of re-
combinant proteins in mammalian cells, a strong viral promoter/
enhancer or a cellular promoter/enhancer combination known to
be particularly active to a certain host cell are commonly used
[4,45,47]. The two elements most widely used are derived from
the simian virus 40 (SV40) [48,49] and cytomegalovirus (CMV)
[50,51]. Nevertheless, other sequences are available for rodent-de-
rived cell lines, such as myeloproliferative sarcoma virus (MPSV)
[52], Rous sarcoma virus (RSV) [53], visna virus [54] and CHO elon-
gation factor-alpha (EF1-a) [45,55].
Elements that stabilize and enhance translation of the primary
transcript: different elements have been used for this effect,
including polyadenylation signals, Kozak sequence and interven-
ing sequences. Polyadenylation signals derived from SV40 [48]
and bovine growth hormone gene [56] are the most commonly
used in mammalian expression cassettes and are thought to pro-
long the half-life of mRNA in cytoplasm and to enable efﬁcient
translation [57]. The Kozak sequence is the optimum consensus
sequence for surrounding the initiator codon of mammalian
genes and is used to improve the translational initiation of mRNA
of the gene of interest [58,59]. Intervening sequences consist of
introns that are usually included in the mammalian expression
vector. In most cases, the gene of interest is isolated as a cDNA
without introns [27]; however, the inclusion of at least one in-
tron between the promoter and the cDNA coding sequence can
result in more efﬁcient cytoplasmatic transport and higher steady
state levels of cytoplasmatic mRNA available for translation
[27,57].
When the mammalian expression vector is used for generation
of a stable producing cell line, an extra sequence, encoding a select-
able marker gene, is used. This selection gene can be present on the
same vector as the recombinant gene or in separate vectors, and
can be driven from a weak promoter, in order to increase the pos-
sibility to obtain high level of producer cells [27]. This usually re-
duces the efﬁciency of stable transfection, with decreased
numbers of surviving cells, but those that survive selection have
the ability to produce higher quantities of the recombinant product
(for further details see next topic) [27].
Furthermore, to improve the efﬁciency of stable transfection,
plasmids can be linearized before this process [60] using restric-
tion enzymes [45]. Nevertheless, supercoiled plasmid DNA mole-
cules will also be converted into linear molecules within the
A. Rita Costa et al. / European Journal of Pharmaceutics and Biopharmaceutics 74 (2010) 127–138 129nucleus after 1–2 h [60]. Either way, the plasmid DNA molecules
will be randomly integrated into the host genome. This random
integration is simple and straight forward, but lacks reproducibility
[46]. Indeed, it has been shown that the site of integration mostly
inﬂuences the transcription rate of the recombinant gene, a phe-
nomenon known as the position effect [27,61]. Depending on the
surrounding chromatin at the integration site, expression of the
product can be high, low or even null [27]. Furthermore, the
expression of the recombinant gene tends to be inactivated (si-
lenced) over time [27,46]. Consequently, the selection of suitable
high-producing clones becomes tedious and time-consuming
[27]. To overcome the position effects, different strategies have
been developed [62–64]. Examples of these strategies include the
use of anti-repressor elements ﬂanking the vectors (i.e. expression
augmenting sequence elements – EASE) [62], the integration of
vectors speciﬁcally into chromosomal loci with open chromatin
(highly transcribed) [63] or the use of nuclear regulatory factors
(matrix-attachment regions (MARS) or scaffold-attachment re-
gions (SARS)) [64,65].
There are situations where a stable and continuous production
is not desired and a regulated or induced gene expression is needed
[4]. For this purpose, inducible mammalian expression systems
have been developed. Initially, they relied on inducers with pleio-
tropic effects on host cells, such as heat shock induction of expres-
sion with its promoter, heavy metal induction of the
metallothionein promoter or glucocorticoid induction of steroid
responsive promoters [66,67]. However, due to the broad range
of effects that they produced and the high basal expression, new
inducible systems have been developed, including the Lac/IPTG
[68], the tetracycline (tet) [69,70], the streptogramin [71] and the
ecdysone [72] systems. All these systems use a regulatory plasmid
for the expression of a repressor or trans-activator and an expres-
sion plasmid containing the regulated promoter linked to the prod-
uct gene [4]. The activity of the repressor or activator is regulated
by the addition of a compound to the culture medium, controlling
the promoter and, consequently, the expression of the gene of
interest [4].
Apart from the problems in the design of expression vectors,
that are common for all recombinant proteins, mAbs have addi-
tional issues that need to be considered. Indeed, their structure
of heavy (HC) and light (LC) chain subunits, whose interaction
inﬂuences the kinetics of mAb assembly [73], results in the need
to express these subunits at optimal stoichiometric ratios (of equal
extent) [73,74]. This has led to the development of different strat-
egies of vector design [4], with the most common consisting of the
use of two vectors, one for each chain, which are co-transfected
into the cells [74,75]. Their relative expression is controlled by
the proportion of each gene used in the co-transfection cocktail.
Nevertheless, this control is not accurate [76,77], and this approach
is considered to be the least efﬁcient to obtain a balanced expres-
sion of both chains, since the site of integration has a major effect
on recombinant gene expression [27]. Indeed, cell-to-cell varia-
tions of gene expression have been detected in the co-transfected
cell pool [78]. Alternatively, a single vector using two identical pro-
moters, one for each chain, can be used; however, this introduces a
risk of recombination events [73]. For a more accurate control of
the relative expression of multiple genes across a transfected cell
pool, a single vector containing multiple compatible inducible pro-
moters (i.e. cyclin E, cdc2, cyclin B1 and aurora A promoters), with
each gene under the control of one independent promoter, can also
be used [79,80]. This allows the introduction of an equal amount of
different genes into each cell [81]. Moreover, by changing the con-
centration of the corresponding chemical inducers, it is possible to
alter simultaneously the expression level of different genes (up to
ﬁve genes, with the currently available inducible promoters) [81–
83].In cases where chemical inducers are not desirable, the use of
constitutive promoters with variable strengths offers an alterna-
tive approach [79]. Nevertheless, due to the lack of promoters with
different strengths, this alternative narrows the range of expres-
sion levels that can be obtained [83]. The development of synthetic
promoters could widen this range, but their application would
probably be cell-line speciﬁc [84,85].
Although a single vector system has the advantage of assuring
equal introduction of genes into cells, the randomness of their inte-
gration into the cell genome remains a problem that results in
inaccurate control of the relative expression of these genes [86].
3.2. Transfection methods
The introduction of the desired product gene into the host
mammalian cell can be performed by a diversity of methods and
systems, in a transient or stable way, whose choice is again depen-
dent on the application intended, as well as economic and techni-
cal factors.
3.2.1. Transient versus stable gene transfection
Production of mAbs in mammalian cells for clinical or commer-
cial purposes is usually done by stable transfection [27]. With the
stable transfection technology, it is possible to obtain a continuous
expression of the product by mammalian cells over prolonged peri-
ods of time [4]. Ultimately, this allows the delivery of larger quan-
tities (kg/year) of protein from cells [87].
A stable transfection is accomplished by the integration of the
DNA of the product gene into the genome of the host cell [4]. To
guarantee the integration, a marker gene is usually transfected in
conjunction with the gene of interest, and the transfected cells
(producing the mAb) are identiﬁed and selected by the character-
istic provided by the product of the gene marker. This is, however,
a labor-intensive and time-consuming step that involves consider-
able investment of resources/equipment [4,87]. Therefore, the
need for quicker and more economical approaches for mAb pro-
duction is evident [87] and can be provided by transient transfec-
tion. Although very similar, stable and transient transfection can be
distinguished by the elimination of the steps of identiﬁcation and
selection of cells that have integrated the plasmid into the genome
in transient transfection. This results in a faster process for obtain-
ing mAb-producing cells. Since the product DNA is maintained/
replicated as an extrachromosomal unit [4], the expression ability
is rapidly lost, only allowing the production of small (milligram to
gram) quantities of mAbs [4,88]. Therefore, transient expression
systems are not yet suitable for large-scale production but are very
useful for high throughput screening in drug discovery processes,
in vivo evaluation and early product analysis [4,87,88]. Moreover,
it can be used with several cell lines (for example, COS [89],
HEK-293 [39,40], CHO [90] and BHK [40]).
Due to the divergence between stable and transient systems in
terms of plasmid insertion into the genome, the factors inﬂuencing
the overall expression level of the transfected cells also differ. For
transient systems, the efﬁciency of transfection is one of the most
important factors, consisting in the percentage of cells taking-up
and expressing DNA. On the other hand, in stable systems, the fre-
quency of DNA integration into the chromosome (copy number)
and the position of integration become more important [4]. Never-
theless, for both systems, the expression levels are strongly af-
fected by the strength of the promoter driving the expression of
the product gene [4,88].
3.2.1.1. Gene marker for stable transfection. As mentioned above, for
stable transfection, a marker gene is usually transfected with the
gene of interest, conferring a selective advantage to the host cells
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reductase (DHFR) and the glutamine synthetase (GS) [23,27,29].
The DHFR expression system, commonly used with CHO cells
[91], is based on the dhfr gene coding for the DHFR enzyme, which
is involved in nucleotide metabolism [27], catalyzing the conver-
sion of dihydrofolate to tetrahydrofolate [92]. In this system, the
selective advantage given to the transfected cells is the resistance
to geneticin. Therefore, selection is performed by culturing the
cells in medium lacking hypoxanthine and thymidine (H/T) [27]
and containing geneticin [92]. Furthermore, this system allows a
process of gene ampliﬁcation that ultimately increases the cell
capacity of production, by the use of methotrexate (MTX), a drug
that inhibits the DHFR enzyme. Using increasing concentrations
of MTX, transfected cells containing the dhfr gene will have to in-
crease their capacity for DHFR synthesis, by amplifying the dhfr
gene [14,92], in order to survive. As the ampliﬁcation unit is much
larger than the size of the dhfr gene, the gene of interest that is lo-
cated in the same expression vector as the dhfr gene or adjacently
resides in the host chromosomal DNA is co-ampliﬁed [93].
In contrast, the GS systemTM (Lonza) exploits the glutamine
metabolism in mammalian cells. Glutamine formation in mamma-
lian cells follows an enzymatic pathway of biosynthesis from glu-
tamate and ammonium using the GS enzyme [94]. Without
glutamine in the growth medium, this GS enzyme is essential for
the survival of mammalian cells in culture [27,94]. Since some cell
lines, such as mouse myeloma lines [29], do not express sufﬁcient
GS to survive, it is possible to use a transfected GS gene as a select-
able marker by permitting growth in a glutamine-free medium
[28,94]. Cell lines that express sufﬁcient GS to survive (i.e. CHO cell
lines) can also be used with the GS system [95] by the application
of methionine sulphoximine (MTS), an inhibitor of the endogenous
GS activity [94]. Thus, only the transfectants with additional GS
activity (i.e. the GS gene) are able to survive [94]. MTS also allows
gene ampliﬁcation using increasing levels of this toxic drug, such
as the MTX in the DHFR system.
The GS system has a time advantage over the DHFR system dur-
ing development, and requires fewer copies of the recombinant
gene per cell [96], allowing a faster selection of high-producing cell
lines [94]. Currently, there are over 50 products in clinical trials





(Medimmune) that use the GS system [28].
Apart from these two traditional gene markers, other expres-
sion systems for transfection have been developed, such as the OS-
CARTM system from the University of Edinburgh. This system is
based on a series of partially disabled minigene vectors that encode
for hypoxanthine phosphoribosyltransferase (HPRT), essential for
purine synthesis via the normal cellular salvage pathway [97].
HPRT-deﬁcient mammalian cells transfected with one of these
minigenes along with the gene of interest are placed in a selective
Hypoxanthine Aminopterin Thymidine (HAT) medium that blocks
de novo purine synthesis. Consequently, cell survival becomes
dependent on the salvage pathway using a disabled HPRT enzyme,
and only the transfected cells are able to grow. Furthermore, since
large amounts of the disabled HPRT enzyme are required for cell
survival, gene ampliﬁcation occurs. This implies that selection
and ampliﬁcation occur in a single step, providing a time advan-
tage of the OSCARTM system over both DHFR and GS systems that
require multiple rounds of ampliﬁcation after selection. Apart from
being quicker, this expression system has also been shown to
achieve higher expression yields, with lower costs of goods, due
to the absence of the specialized media and toxic chemicals needed
for the more traditional systems. Moreover, the high yields of pro-
tein production that have been obtained with OSCARTM have
shown to be stable [12]. Nevertheless, this system still needs to
be further evaluated on its applicability for a wide range of cell
types, media, scalability and bioreactor cultures.3.2.2. DNA delivery systems
For the introduction of the gene of interest (and the marker
gene in stable transfection) into mammalian cells, several DNA
delivery systems have been developed, with non-viral gene trans-
fer approaches being the most suitable for manufacturing purposes
[27]. These methods include calcium–phosphate precipitation,
electroporation, lipofection and polymer-mediated gene transfer
[98–101]. It is impossible to evaluate whether any of these meth-
ods is better than the others because comprehensive and compar-
ative studies are still lacking [27].
3.2.2.1. Calcium–phosphate precipitation. Although many methods
have been developed for transferring plasmid DNA into cells to
generate recombinant cell lines, calcium–phosphate co-precipita-
tion (CaPO4) remains one of the most widely used [102]. This
method, ﬁrst described in 1973 by Graham et al. [98], is based
on the formation of a ﬁne DNA precipitate or complex that enters
mammalian cells via an endocytic vesicle [98,103] and has the
advantages of being inexpensive and working in a wide range of
cell types [4].
However, the efﬁciency and reproducibility of this method is
low, and several strategies have been studied to improve the meth-
odology. These include post-transfection treatments with dimethyl
sulfoxide (DMSO), glycerol or chloroquine [103], to support the
transfer of a high plasmid copy number into cells, resulting in in-
creased transient and stable mAb production [102,104].
Nevertheless, the still low efﬁciencies of this method, the
requirement of serum in the medium during transfection [105],
as well as the high variability of the transfection outcome depend-
ing on minor alterations in procedure (relative concentrations of
reagents and DNA) or environment (pH, temperature) [4], has led
researchers to ﬁnd better gene transfer methods [105].
3.2.2.2. Electroporation. Electroporation is a simple and rapid meth-
od used for gene delivery into cells [4,92]. This is accomplished by
a pulsed electric ﬁeld that disrupts the voltage gradient across the
plasmamembrane, creating reversible pores that allow the entry of
DNA into the cell [106]. Though it is less cell type speciﬁc than
other transfection methods, parameters like peak voltage and fall
time of the discharge waveform need to be optimized in each case
[4]. Furthermore, this method usually results in lower post-trans-
fection cell viability [4]. Consequently, this method is more com-
monly used in small assays that require rapid and low levels of
production.
3.2.2.3. Lipofection and polyfection. Lipofection and polyfection are
the most recent, and probably most simple, transfection methodol-
ogies for gene delivery in a diversity of cells [4].
Lipofection consists of cationic lipid-mediated gene transfer
into the cell, where cationic liposomes form a complex with the
negatively charged DNA [4]. This method can be performed in
the presence or absence of serum, with little or no toxicity [4], as
well as with attached and suspended cells [87]. However, the
amount of DNA and lipid used as well as the ratio between them
affect transfection efﬁciencies and therefore still need to be opti-
mized [107].
Polyfection, for its turn, refers to gene transfer mediated by cat-
ionic polymers (such as polycation polyethylenimine, PEI
[108,109]) and dendrimers [4]. They interact with DNA forming a
polyplex that protects DNA from degradation before reaching the
cell nucleus [110]. This method can be used for gene delivery in
serum-free suspension cultures [108,109]. As with lipofection,
the optimal protocol needs to be empirically determined for each
cell culture [4].
Although several methods have been developed for cell trans-
fection, it is obvious that much work is still to be done. It has been
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mids into cells is also the one generating cell lines with the highest
speciﬁc productivity [105]. However, the methods mentioned do
not control the amount of functional plasmid that enters the cell
nucleus, thus limiting the reproducibility of the generation of
high-producing cell lines [105].
Furthermore, it would be important to reduce the need for
empirical optimization of the transfection method for each cell line
used, granting time and cost savings. This would be possible by the
ideal development of a non-cell-speciﬁc method for the achieve-
ment of high-expression levels.
3.3. Selection
Cells transfected are subjected to a process of screening/selec-
tion that lasts from growth recovery after transfection, through
single-cell cloning, ampliﬁcation, suspension and serum-free adap-
tation, until ﬁnal clone selection [111].
After transfection, mAb-producing cells are selected by being
subjected to speciﬁc culture conditions that only allow survival
and growth of cell clones expressing the marker gene product
[44]. These clones are transferred as single cells to a second culti-
vation vessel, where the cultures are expanded to produce clonal
populations [27]. Clones are then evaluated in terms of growth
and product (mAb) titer, and the highest producers are selected
for another round(s) of cultivation and analysis, to conﬁrm
whether the levels of productivity are maintained [27,111].
These initially selectedcloneshaveaproductivity thatmaynotbe
optimal. To improve this, and as mentioned previously, cells can be
subjected to repetitive rounds of exposure to higher concentrations
of inhibitors of selective markers (MTX, MTS), which results in gene
ampliﬁcation [4,111]. The gene of interest expressing the antibody
may be co-ampliﬁedwith the selectivemarker gene, resulting in en-
hanced expression levels and mAb productivity [4,111].
Traditionally, ampliﬁcation is performed by the limiting dilu-
tion approach and is a time- and labor-consuming screening pro-
cess. Indeed, the screening and selection of a highly productive
and stable clone in a short time frame is still currently a major
challenge [111]. Furthermore, due to the high workload it repre-
sents, the selection is made based solely on one feature – the
expression level. However, other speciﬁc cell properties may also
be important for the production process and should be included
in the screening, such as, the ability of a clone to grow in serum-
free medium, resistance to apoptosis, cell characteristics (i.e. cell
size has been considered the major cellular determinant of produc-
tivity [112]), production kinetics suitable for the type of process
used, stability of product formation and a general robustness of
the cell line under the stress and shear conditions found in biore-
actors [113]. Particularly, it is important that the level of mAb pro-
duction of the selected clones remains stable for long periods of
time [96,97], since the scale-up of the culture process to industry
levels takes signiﬁcant time. Generally, production levels should
remain stable for at least 60 generations beyond production of a
manufacturer’s Working Cell Bank [96,113]. In the presence of
the drug selective pressure (i.e. MTX and MTS), the production lev-
els are usually stable [29,96]. However, due to the toxicity, high
costs and complicated downstream puriﬁcation associated with
these drugs, it would be important to guaranty stability of produc-
tion without their use [27,97,111,113]. Studies have shown that in
the absence of drug selective pressure, there are signs of instability,
with decreasing levels of production [23,96,114], which is often
attributed to loss of recombinant gene copies during long-term
culture [114]. To this end, it would be valuable, in terms of both
time and costs, to identify molecular markers that could predict
clone instability, eliminating the need for prolonged culture to con-
ﬁrm long-term stability [97]. Since the site of insertion of the prod-uct gene in the cell genome is known to affect stability of
production, studies on the exact site of insertion, for example,
using ﬂuorescent in situ hybridization (FISH), may be very useful
to identify speciﬁc regions of the genome associated with stability
of recombinant gene expression [97].
Furthermore, other efforts are being made to generate a faster
and simpler method of screening, including characteristics other
than the expression level of cells. Techniques of ﬂow cytometry
and high-speed ﬂuorescence-activated cell sorting (FACS) have
been applied [115,116] with relative success. These techniques rely
upon microdrop methodologies [117,118], labeled anti-Fc antibody
[119], metallothionein green ﬂuorescent protein (GFP) fusion [120]
or surface afﬁnity matrix strategies to capture secreted antibody,
prior to clone isolation [121–123]. One of these techniques is the
Single Cell Secretion Assay developed by Borth et al. [123] that
measures the speciﬁc production rates of individual cells by catch-
ing the secreted product in an artiﬁcial afﬁnity matrix applied to
the surface of viable cells, that was shown to reduce the workload
required to isolate high producers during gene ampliﬁcation by a
factor of 10. This method, followed by ﬂow cytometry cell sorting
combined with culture conditions that bring out a desired cell
property was shown to allow the selection of rare cells with high
production rates, non-growth associated production kinetics and
improved stability in the presence of selective pressure [113].
Multiparameter FACS in associationwith dual intracellular auto-
ﬂuorescent reporter proteins (i.e. GFP) has also been described by
Sleiman et al. [124] to accelerate selection and characterization of
clones. The application of chain-speciﬁc reporter pairs using
two-color intracellular ﬂuorescence by FACS in identifying high-
antibody-producing clones provides an attractive alternative to
single-color immunocytochemical methods of detection [124]. This
technique eliminates the need for complex preparative steps or la-
bor-intensive workﬂows andwas shown to allow a 38-fold increase
in mAb production, within 12 weeks, after only one single round of
FACS [124].
Another approach used to accelerate clone selection involves
the use of miniaturized bioreactors or shake ﬂasks to simulate
the standard production bioreactor conditions [111]. After adapta-
tion of cells to growth in suspension and serum-free medium, an
enriched medium similar to the ﬁnal production medium and a
similar feeding regime can be applied [111]. Thus, the clones more
suitable for maintenance of high-producing levels in these bioreac-
tor conditions can be selected.4. Cell engineering
In recent years, continuous efforts have been made for the
application of genetic engineering approaches to improve the util-
ity of mammalian host cells in recombinant protein production.
These techniques are used in an attempt to modify speciﬁc features
of the host cells in order to enhance the protein yield as well as the
quality [4,11,14,125]. Speciﬁcally, manipulations have been direc-
ted primarily at controlling cell growth, preventing cell death, pro-
moting post-translational protein processing and folding [14] or
enhancing the ability to grow in nutritionally deﬁned media
[126,127]. To achieve this, strategies of anti-apoptosis, metabolic
engineering, engineering cells for hypothermic growth, as well as
engineering of molecular chaperones and post-translational pro-
cessing have been approached.4.1. Anti-apoptosis
Anti-apoptosis engineering has been one of the main areas of
research in the ﬁeld of cell line development for protein production
[4,11,128]. Mammalian cells are sensitive to their environment,
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factor withdrawal, oxygen limitations, toxin accumulations, osmo-
larity decreases and excessive shear-stress levels, programmed cell
death (apoptosis) is induced [14,128–131].
Therefore, it is of considerable value to be able to down-regu-
late or prevent apoptosis in culture in order to increase the density
of viable cells by suppressing cell death, resulting in extended cul-
ture lifespan, and to increase the cell-speciﬁc productivity by
maintaining the cellular activity. This will, ultimately, enable the
maximization of the volumetric productivity of therapeutic pro-
teins [11,14,125,132].
Different anti-apoptotic strategies have been studied
[11,133,134]. Among them, non-genetic approaches are the easiest
to implement in existing cell culture processes. They rely on delay-
ing the onset of apoptosis, by periodic nutrient feeding after deter-
mining the time at which nutrients are depleted [11], the use of
galactose instead of glucose as a carbon source [133], or the use
of nucleosides such as adenosine [134].
Another approach consists in the overexpression of anti-apop-
totic genes that mammalian cells possess. Indeed, the process of
cell death involves a series of biochemical steps with activation
of pro-death factors and proteins inside the cells that lead to the
inactivation of essential mechanisms for life [135]. However, mam-
malian cells also have genes encoding for anti-death proteins that
prevent the activation of the apoptosis cascade [132]. By increasing
the expression or activity of one or more of these anti-death pro-
teins, it may be possible to enhance cell survival under stressful
conditions [132]. The anti-apoptotic genes already tested, with po-
sitive results in terms of both cell density and protein titer are Bcl-
2 [130,136,137], Bcl-xL [130,136,138], 30Kc6 [125], Aven
[132,139], XIAP [140], CrmA [141] and E1B-19K [132,142]. Further-
more, anti-apoptotic chemicals have also been used, such as sura-
min [143], N-acetylcysteine (NAC) [144] and silkworm hemolymph
[145], offering protection against apoptosis under serum-free con-
ditions [11].
As the cellular pathway leading to apoptosis involves the activa-
tion of members of caspases [146], the inhibition of caspase
expression has also been tested as an anti-apoptosis strategy
[147]. Speciﬁc caspase inhibitors have been tested, but their high
cost for large-scale cultures might make them unaffordable [11].
Therefore, strategies of down-regulation of these caspases were
tested, aiming primarily for caspase-3, since it plays a key role in
apoptosis and is critical to cellular commitment to irreversible
apoptotic cell death [148]. Silencing of caspase-3 using antisense
technology [149,150] and co-down-regulation of caspase-3 and
caspase-7 [151] are some of the methodologies used. However, this
down-regulation has shown to be beneﬁcial only at times, because
cells tend to compensate for the lack of some effectors by up-reg-
ulating others. Therefore, in caspase silencing, the interrelationship
between molecules in a cell and the cell’s competence to cope with
changes needs to be considered [11].
Another strategy of anti-apoptosis is based on the inhibition of
cell cycle progression. Indeed, control of progression through the
cell cycle may signiﬁcantly increase cell density and productivity
in mammalian cell cultures [4,152]. It has been shown that there
is a critical relationship between the emergence of cell death and
cell cycle progression, further implying that conditions that sup-
port less than maximal passage through the cell cycle may protect
cells against apoptosis [152,153]. Attempts made in this sense in-
clude modulation of c-jun [154], growing under glutamine limita-
tion [131], inducible expression of p27 [70,136] and p21cip1
[137,155], and use of rapamycin [152,156]. They result in slower
progression through cell cycle, with reduced cell death (and in-
creased viability), enabling viable proliferation to higher maximum
viable cell densities and, therefore, increasing speciﬁc mAb produc-
tion [152].A combination of different strategies, or the use of multiple
anti-apoptosis genes, can be favorable and improve protection
against apoptosis, as it has been shown in some studies [137,139].
Furthermore, it has been suggested that the optimal anti-apop-
tosis strategy may involve lower level of expression of anti-apopto-
sis genes during the exponential phases of cell growth, followed by
their overexpression during the post-exponential phase in which
cells are subjected to more severe environment stresses [132].
Nevertheless, this control demands the development of inducible
technologies that could be readily tuned to different expression
levels and at the same time can be affordable and adaptable to
scale-up for larger bioreactors [132].
4.2. Metabolic engineering
Another focus of genetic manipulation has been metabolic engi-
neering as a way to indirectly increase cell growth and volumetric
production, through the inhibition of the accumulation of toxic
metabolic by-products, such as lactate and ammonia [4,11]. Two
approaches are commonly used: improvement of the efﬁciency of
central carbon (primary) metabolism and the reduction in lactate
accumulation [4]. The ﬁrst approach is usually based on redirecting
cells into pathways using energy more efﬁciently [11], for example,
overexpressing pyruvate carboxylase which increases the ﬂux of
glucose into the tricarboxylic acid cycle [157]. For the second ap-
proach, partial disruption of the lactase dehydrogenase A (LDH-
A) gene has been used [37,158], as well as the overexpression of
urea cycle enzymes, carbamoyl phosphate synthetase I and orni-
thine transcarbamoylase that reduce the accumulation of ammo-
nium ions in the culture medium [159].
4.3. Engineering cells for hypothermic growth
Low temperature cultivation is a simple and very effective
method of controlling cell proliferation [160]. It was observed that
mammalian cells growing between 27 C and 32 C have a low spe-
ciﬁc growth rate, but maintain a high viability and reduced con-
tamination by endogenous cell proteins [161,162]. Also, low
temperature cultivation has been associated with increases in spe-
ciﬁc productivity (q) [161,163,164]. However, the increase in spe-
ciﬁc productivity observed at low temperature does not result in
a similar increase in the volumetric productivity, due to the re-
duced cell growth rates [11]. In fact, an inverse relationship be-
tween cell-speciﬁc growth rate and speciﬁc productivity has
been observed [161,165].
Consequently, genetic engineering strategies to improve volu-
metric recombinant protein production at low temperatures have
been developed, yet with mixed and not so positive results
[11,166]. These strategies focus on alleviating the growth suppres-
sion at low temperature and include down-regulation of cold-
inducible RNA-binding protein (CIRP) with the intent to boost
growth properties at hypothermia [24,167] and adaptation of cells
to low culture temperature. However, although improving cell
growth at low temperatures, neither attempt has proved to be efﬁ-
cient in increasing cell productivity [24,167].
Therefore, the molecular mechanisms associated with slow
growth rate at lower culture temperature need to be further stud-
ied in order to be exploited as a tool for host cell engineering [11].
Nevertheless, it has been usually observed that high producer cell
lines have slower growth rates due to the additional metabolic
burden of production thrust on them [11].
Alternatively, a biphasic process, where cells are ﬁrst cultivated
at 37 C in the growth phase for high growth rates followed by a
temperature shift to low culture temperature in the production
phase for high productivity may be used to increase the volumetric
productivity [164,168].
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Since mAbs are secreted proteins, and the endoplasmic reticu-
lum (ER) has a quintessential role in the secretory pathway of cells,
many studies have been done to understand the relationship be-
tween the production of mAbs and the regulation of ER proteins
in the host cells [169]. It has been observed/suggested that the
rate-limiting steps in protein expression may be translation or
post-translational processes, since the amount of protein secreted
does not increase proportionally with the gene copy number
[170,171]. Some studies have demonstrated that the up-regulation
of the ER proteins involved in protein secretion is associated with
high-levels of protein production [169,172,173].
Therefore, there has been some interest in host cell engineering
strategies targeting the secretory pathway, in order to enhance
mAb production [11,14,169]. The most common approach involves
the overexpression of ER chaperones, which has achieved varied
results in mammalian cells [11,169,174–176]. Actually, it has been
observed that the effects of molecular chaperones on protein pro-
duction is dependent on several factors, including the expression
system used, the target proteins and the chaperones concerned
[11]. For example, protein disulﬁde isomerase (PDI) has been used
for chaperone engineering, with its overexpression on protein-pro-
ducing cell lines resulting in either enhanced [172,176,177], de-
creased [175] or even unaffected productivities [11,175]. When
in combination with the heavy chain-binding protein (BiP), de-
creased productivity was observed [174]. Studies of single overex-
pression of BiP showed its relation to increased productivity
[172,173]. However, in another study, it was the reduction in the
level of BiP expression, rather than its overexpression, that resulted
in improved productivity [178].
Other chaperones have also been tested, such as the overex-
pression of ERp57 [179], glucose regulated protein 94 (GRP94)
[176] or endoplasmin [172], or even the simultaneous expression
of lectin-binding chaperones, calnexin and calreticulin [180],
which resulted in increased productivities.
Since the gene regulation system in mammalian cells is so com-
plex, targeting single components of the secretory pathway in iso-
lation may not be the best approach for increasing productivity
[11,169]. Indeed, the overexpression of several chaperones,
co-chaperones, holdases and/or foldases, concomitantly, in a func-
tionally meaningful ratio to modulate the secretory machinery in a
global fashion might be a better strategy [11]. A strategy for this
global modulation may target the X-box-binding protein 1 (XBP-
1S), which is a regulator of multiple critical genes in the secretory
pathway [169]. Ku et al. [169] demonstrated that the overexpres-
sion of the XBP-1S is not a strategy that indiscriminately enhances
recombinant protein production, but one which is effective in
relieving secretory bottlenecks that may be encountered in some
production systems [169].
4.5. Engineering of post-translational processing (glycosylation)
While optimizing processes to achieve high yield, it is critical to
monitor product quality changes at every stage of development.
Glycosylation variation, which can impact in vivo mAb functions
and stability, is one of the most sensitive quality-related attributes.
Cell culture factors, host cell selection and protein speciﬁc features
inﬂuence the glycosylation pathway, leading to the production of
proteins with variable/suboptimal clearance or functionality
[4,181]. In an attempt to achieve/guarantee a correct level of glyco-
sylation on proteins produced in mammalian cell culture and to
improve effector functions (such as antibody-dependent cell med-
iated cytotoxicity (ADCC) and complement-dependent cytotoxicity
(CDC)), recent studies have focused on glycosylation engineering
with speciﬁc manipulation of oligosaccharide structures [25,182].This manipulation can be achieved by the overexpression of
appropriate glycosyltransferases, either enhancing glycan
quality, by increasing homogeneity of native structures, or intro-
ducing non-host cell residues to specialize glycan quality and func-
tion [4]. Examples of the former include the overexpression
of galactosyltransferase (increase in the galactose levels), sialyl-
transferase (increase in the sialic acid levels) [183] and N-acetyl-
glucosaminyltransferase III (increase the fraction of bisecting
N-acetylglucosamine residues) [184]. The overexpression of N-
acetylglucosaminyltransferase III (GNTIII) can be achieved by
transfecting cells with the GNTIII enzyme and results in non-
fucosylated mAbs that have improved ADCC and CDC functions
[184,189,190]. Non-fucosylated mAbs can also be obtained using
cells with a-1,6-fucosyltransferase gene (FUT 8) knockout
[187,188].
For the second approach, examples include the introduction of
sialic acid in an a-2,6 linkage to glycoproteins synthesized by
CHO and BHK cells that lack the speciﬁc sialyltransferase responsi-
ble for this transfer [185,186].
New cellular engineering strategies to improve cell viability and
productivity of recombinant pharmaceuticals are being developed.
However, the current understanding of cellular and molecular con-
straints on the function of engineered mammalian cells in vitro is
still very limited. So, this needs to be improved to allow the ra-
tional enhancement of a certain cell function (i.e. productivity),
rather than the current trial-and-error approach [172,191].
It has been suggested that the most effective strategies for engi-
neering cell culture performance in vitro need to rely on the spe-
ciﬁc knowledge of the system in question and on the use of
quantitative data. Furthermore, these strategies should derive from
validated predictive models and involve simultaneous modulation
of the activity of different cell components [172]. Indeed, the next
generation of cell engineering strategies should be multigenic in
design and reproduce the multigenic control of cell function
[192]. However, currently, there is lack of relevant data concerning
the dynamic levels of the multiple discrete components of a mam-
malian system and an incomplete understanding of their interac-
tions [193].5. Adaptation to new culture conditions
The most common processes for large-scale production of
biophamarceutical products, including mAbs, require suspended
cells and also the use of serum-free medium. Therefore, after
obtaining mAb-producing cells, they need to be subjected to a pro-
cess of adaptation to these new conditions, which, nevertheless,
can impose some limitations to the development of the process
of production.5.1. Suspension
Large-scale production of mAbs in bioreactors is usually per-
formed with cells growing in suspension. This is because the sur-
face/volume ratio in suspension cultures is much higher than in
adherent cultures [4], allowing increased cell densities and produc-
tivities to be reached. However, most mammalian cells naturally
grow adherently and their growth in suspension demands a pro-
cess of adaptation. This adaptation is not possible to all cell types,
which limits the choice of the cell line and can be very time-con-
suming [62].
Adaptation of cells that are grown adherently in serum-contain-
ing medium to growth in suspension is usually accomplished using
the same medium but changing cells to spinner vessels [4], shake
ﬂasks [57,194] or even roller bottles [195], with agitation of 50–
80 rpm [4]. To guarantee a successful adaptation some parameters
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process of adaptation, there is usually a high proportion of cells
that do not survive. Therefore, it is of extreme importance that
the low proportion of survival cells is in sufﬁcient number so that
expansion does not take too long or becomes stalled. For this rea-
son, the suspension culture should be initiated with a suitable high
cell density. Furthermore, a strict monitoring should be maintained
over the culture during the adaptation phase, with cell growth and
viability evaluated frequently for several passages. Furthermore,
productivity levels should also be assessed, since they can change
during adaptation [4].
To ease the passage from adherent to suspension culture, two
approaches can be followed: media optimization (for example,
altering cation concentration) [192] and the use of specially treated
glass and plasticware [4]. Also, since cells are subjected to constant
mixing/agitation during suspension culture, shear-stress can be in-
ﬂicted on cells. To minimize damage caused by agitation, shear-
protectants such as Pluronic F68 are commonly used [13]. It should
be mentioned that any additions to the culture have implications
to downstream processing (puriﬁcation) and, therefore, need to
be thoroughly analyzed.
5.2. Serum-free medium
Serum is an essential component of any culture medium sup-
porting cell proliferation. However, serum has many disadvantages
for the production of human therapeutics, such as: (i) the variable
concentrations of components between batches which jeopardize
the process consistency; (ii) the burden put on downstream pro-
cessing [196,197]; (iii) the high costs [196] and (iv) the risk of
transmission of animal diseases to humans. Therefore, the use of
serum-free (SF) or protein-free (PF) media is currently one of the
main goals of commercial cell culture [4,198]. However, this re-
quires the development of a speciﬁc medium for each cell line,
since there is no universal SF medium [197].
Extensive efforts have been made in order to identify serum-
substituting supplements that fulﬁll the complex nutritional
requirements of mammalian cells, which is usually done by time-
consuming methodologies [199,200]. These include the Ham’s
approach (gradual reduction in the concentration of undeﬁned
supplements in the culture) [201], the Sato’s approach (reconstruc-
tion of the extracellular environment involved in supporting cell
growth in vivo) [202], the top–down approach (taking of an existing
serum-supplemented formulation for a similar cell line and selec-
tion of the constituents that are stimulatory for growth) and the bot-
tom–up approach (selection of a basal medium, analysis of
individual components for their effects on growth and combination
of them to make a serum-free formulation) [4]. To overcome this,
statistical experimental design can be used as an efﬁcient way of
screening large numbers of medium supplements and identifying
the most important [203], in a time-efﬁcient way, accelerating the
process of SFmedia development. Furthermore, in the development
of SFmedia for mAb production, components important for produc-
tion (and not just cell growth) should also be considered.
Nevertheless, even with chemically deﬁned SF media, cell adap-
tation to the new medium can be a long process, since it is not yet
physiologically well understood and, therefore, more difﬁcult to
perform and more time-consuming [204] than adaptation of cells
to suspension in serum-containing media [4].
For the adaptation to SF media, basically two approaches can be
used: a direct approach, where serum is completely removed in a
single step and a gradual/sequential approach, where serum con-
centration in the medium is slowly reduced [4]. In both ap-
proaches, cell growth occurs slowly, with low viabilities obtained
for several passages, demanding constant monitoring [4]. Although
there is still no easy way to accelerate the adaptation, the use ofhigh inoculum densities [204,205], as well as media exchanges
using centrifugation of cells and resuspension in fresh media (to
remove waste products and to maintain an adequate seeding den-
sity) [4], can somewhat abbreviate the process. Furthermore, in
some cases, during cell adaptation to SF medium, the selective
pressure on the gene of interest must be reduced, so that cells
can adapt more easily. However, even in lower concentration, the
selective pressure should be maintained so that the high-level gene
expression is preserved [4]. Also, it is interesting to note that SF
adaptation can even be advantageous in terms of mAb production,
as reported in several works that indicate signiﬁcantly increased
mAb production kinetics in SF medium with respect to those done
in serum-containing medium [206,207].6. Conclusions
The increasing importance of mAbs in therapeutic applications,
occurring in recent years, has led to the rapid development of tech-
niques/strategies for their large-scale production. Efforts continue
on optimization of mAb production, but they usually focus on bio-
reactor design and/or operation. However, the procedures per-
formed before bioreactor culture, such as transfection of the gene
of interest into the cells, selection of the most appropriate clone
and adaptation to different culture conditions, have been shown
to strongly impact the expression levels possible to achieve in lat-
ter stages. Consequently, optimization should include and begin
with these initial steps of creation of a mAb-producing cell line.
Furthermore, these procedures are very time-consuming and,
therefore, the ones most responsible for the delays observed until
a mAb becomes commercially available. This is a major drawback
for biopharmaceutical companies, whose success highly depends
on how fast they can put their products in the market.
Studies made in this area show that cell engineering, in partic-
ular, holds a great potential to surpass the obstacles currently
encountered. Indeed, developments in this ﬁeld may allow a better
control over cell growth and productivity, enhance their ability to
adapt to new conditions, as well as increase the quality of the prod-
uct obtained. However, some results have been contradictory,
which can be related to the lack of knowledge about cellular
mechanisms and speciﬁcally their interconnections. If the current
know-how is not expanded, success will strongly depend on
trial-and-error experiments, and progress in this ﬁeld will be
dependent on new discoveries and their application.References
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